Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

9 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(46.2%)
N/A
3(23.1%)
Phase 3
3(23.1%)
Phase 2
1(7.7%)
13Total
Phase 4(6)
N/A(3)
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT04221152Phase 3Unknown

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

Role: lead

NCT04018365Phase 3Unknown

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Role: lead

NCT01261234Not ApplicableCompleted

Carotid Artery Stenting With Cilostazol Addition for Restenosis

Role: collaborator

NCT03552432Phase 4Unknown

The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography

Role: lead

NCT03657758Phase 4Unknown

Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]

Role: lead

NCT03665389Not ApplicableUnknown

Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients Undergoing TAVR

Role: lead

NCT03529253Phase 4Unknown

Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound

Role: lead

NCT03540381Completed

Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization

Role: lead

NCT03533959Unknown

To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy

Role: lead

NCT03192579Phase 4Completed

Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

Role: lead

NCT02014818Not ApplicableUnknown

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent

Role: lead

NCT03021382Completed

Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography

Role: lead

NCT00231738Phase 4Completed

Protective Effect of EPA on Cardiovascular Events

Role: lead

NCT01918384Phase 2Unknown

Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy

Role: lead

NCT01460550Phase 3Unknown

A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction

Role: lead

NCT01942044Phase 4Unknown

Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)

Role: lead

NCT01689688Unknown

Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography

Role: lead

NCT00287794Unknown

Quality of Sleep in Patients With Rheumatoid Arthritis

Role: lead

All 18 trials loaded